120 related articles for article (PubMed ID: 37311695)
1. Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
Atrash S; Robinson M; Taneja A; Paul B; Cassetta K; Ndiaye A; Varga C; Block J; Lipford EH; Smith ET; McCall CM; Thurston V; Foureau D; Usmani SZ; Voorhees PM; Bhutani M
Eur J Haematol; 2023 Sep; 111(3):373-381. PubMed ID: 37311695
[TBL] [Abstract][Full Text] [Related]
2. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
[TBL] [Abstract][Full Text] [Related]
4. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma.
Alexandrakis MG; Passam FH; Kyriakou DS; Dambaki K; Niniraki M; Stathopoulos E
Am J Clin Oncol; 2004 Feb; 27(1):8-13. PubMed ID: 14758126
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
7. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
Ely S; Forsberg P; Ouansafi I; Rossi A; Modin A; Pearse R; Pekle K; Perry A; Coleman M; Jayabalan D; Di Liberto M; Chen-Kiang S; Niesvizky R; Mark TM
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):825-833. PubMed ID: 29051077
[TBL] [Abstract][Full Text] [Related]
8. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.
Al Saleh AS; Parmar HV; Visram A; Muchtar E; Buadi FK; Go RS; Dispenzieri A; Kapoor P; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kourelis TV; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):596-601. PubMed ID: 32360276
[TBL] [Abstract][Full Text] [Related]
9. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance.
Marković O; Marisavljević D; Cemerikić V; Vidović A; Perunicić M; Todorović M; Elezović I; Colović M
Med Oncol; 2008; 25(4):451-7. PubMed ID: 18449811
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
Hematology; 2023 Dec; 28(1):2161222. PubMed ID: 36607148
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
[TBL] [Abstract][Full Text] [Related]
13. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis.
Ek S; Björck E; Porwit-MacDonald A; Nordenskjöld M; Borrebaeck CA
Haematologica; 2004 Jun; 89(6):686-95. PubMed ID: 15194536
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Kastritis E; Migkou M; Dalampira D; Gavriatopoulou M; Fotiou D; Roussou M; Kanellias N; Ntanasis-Stathopoulos I; Malandrakis P; Theodorakakou F; Sevastoudi A; Eleutherakis-Papaiakovou E; Triantafyllou T; Terpos E; Katodritou E; Dimopoulos MA
Am J Hematol; 2022 Sep; 97(9):1142-1149. PubMed ID: 35731917
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
17. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
18. [Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance].
Marković O; Marisavljević D; Cemerikić V; Vidović A; Bakrac M; Perunicić M; Suvajdzić N; Colović M
Vojnosanit Pregl; 2005 Jan; 62(1):33-8. PubMed ID: 15715347
[TBL] [Abstract][Full Text] [Related]
19. High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.
Li M; Bai Y; Sun X; Wang H; Li W; Xiao X; Chen Y; Sun K
Discov Med; 2023 Apr; 35(175):157-167. PubMed ID: 37105925
[TBL] [Abstract][Full Text] [Related]
20. Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients.
Cao Y; Gong Y; Zhou X; Sun C
Hematology; 2023 Dec; 28(1):2208914. PubMed ID: 37145015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]